Patents by Inventor Brian K. Hubbard
Brian K. Hubbard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141029Abstract: Provided herein are methods and compositions related to the treatment of sepsis using anti-ANGPTL3 antibodies.Type: ApplicationFiled: March 2, 2022Publication date: May 2, 2024Inventors: Brian K. Hubbard, Michael H. Serrano-Wu, Charles D. Meyers
-
Publication number: 20230407285Abstract: The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.Type: ApplicationFiled: January 25, 2023Publication date: December 21, 2023Inventors: Michael H. Serrano-Wu, Brian K. Hubbard, Virendar Kaushik, Doug Daniels
-
Patent number: 11819495Abstract: The present disclosure provides methods related to treating or preventing gastrointestinal dysfunction in a subject in need thereof, which include the use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. The disclosure also provides pharmaceutical compositions comprising a DGAT1 inhibitor, or pharmaceutically acceptable salts or esters thereof, useful for the treatments described herein.Type: GrantFiled: December 30, 2021Date of Patent: November 21, 2023Assignee: Anji Pharmaceuticals Inc.Inventors: Brian K. Hubbard, Michael H. Serrano-Wu
-
Patent number: 11679146Abstract: The present disclosure provides methods related to inhibiting or treating pancreatitis in a subject in need thereof, which include the use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor. The disclosed PCSK9 inhibitors and compositions including them can be used for treatment, inhibition, or prevention of pancreatitis in a subject. Treatment methods can include administering to the subject a therapeutically effective amount of a PCSK9 inhibitor.Type: GrantFiled: June 4, 2019Date of Patent: June 20, 2023Assignee: Anji Pharmaceuticals Inc.Inventors: Charles D. Meyers, Brian K. Hubbard, Michael H. Serrano-Wu
-
Patent number: 11603523Abstract: The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.Type: GrantFiled: January 16, 2020Date of Patent: March 14, 2023Assignee: AstraZeneca ABInventors: Michael H. Serrano-Wu, Brian K. Hubbard, Virendar Kaushik, Doug Daniels
-
Publication number: 20220193044Abstract: The present disclosure provides methods related to treating or preventing gastrointestinal dysfunction in a subject in need thereof, which include the use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. The disclosure also provides pharmaceutical compositions comprising a DGAT1 inhibitor, or pharmaceutically acceptable salts or esters thereof, useful for the treatments described herein.Type: ApplicationFiled: December 30, 2021Publication date: June 23, 2022Inventors: Brian K. Hubbard, Michael H. Serrano-Wu
-
Patent number: 11224590Abstract: The present disclosure provides methods related to treating or preventing gastrointestinal dysfunction in a subject in need thereof, which include the use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. The disclosure also provides pharmaceutical compositions comprising a DGAT1 inhibitor, or pharmaceutically acceptable salts or esters thereof, useful for the treatments described herein.Type: GrantFiled: March 15, 2019Date of Patent: January 18, 2022Assignee: Anji Pharmaceuticals Inc.Inventors: Brian K. Hubbard, Michael H. Serrano-Wu
-
Publication number: 20210213111Abstract: The present disclosure provides methods related to inhibiting or treating pancreatitis in a subject in need thereof, which include the use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor. The disclosed PCSK9 inhibitors and compositions including them can be used for treatment, inhibition, or prevention of pancreatitis in a subject. Treatment methods can include administering to the subject a therapeutically effective amount of a PCSK9 inhibitor.Type: ApplicationFiled: June 4, 2019Publication date: July 15, 2021Inventors: Charles D. Meyers, Brian K. Hubbard, Michael H. Serrano-Wu
-
Publication number: 20200231584Abstract: The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.Type: ApplicationFiled: January 16, 2020Publication date: July 23, 2020Inventors: Michael H. Serrano-Wu, Brian K. Hubbard, Virendar Kaushik, Doug Daniels
-
Publication number: 20190282549Abstract: The present disclosure provides methods related to treating or preventing gastrointestinal dysfunction in a subject in need thereof, which include the use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. The disclosure also provides pharmaceutical compositions comprising a DGAT1 inhibitor, or pharmaceutically acceptable salts or esters thereof, useful for the treatments described herein.Type: ApplicationFiled: March 15, 2019Publication date: September 19, 2019Inventors: Brian K. Hubbard, Michael H. Serrano-Wu
-
Patent number: 8334111Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: GrantFiled: January 28, 2011Date of Patent: December 18, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Rosana Kapeller-Libermann, Zhidan Wu, Brian K. Hubbard
-
Publication number: 20120177661Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: March 20, 2012Publication date: July 12, 2012Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Publication number: 20120003233Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: January 28, 2011Publication date: January 5, 2012Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Patent number: 7910346Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: GrantFiled: February 17, 2009Date of Patent: March 22, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Rosana Kapeller-Libermann, Zhidan Wu, Brian K. Hubbard
-
Publication number: 20100035339Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: April 30, 2009Publication date: February 11, 2010Inventors: Ruth E. GIMENO, Zhidan WU, Rosana KAPELLER-LIBERMANN, Brian K. HUBBARD
-
Publication number: 20090269332Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: February 17, 2009Publication date: October 29, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Patent number: 7527962Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: GrantFiled: December 7, 2005Date of Patent: May 5, 2009Assignee: Millenium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
-
Publication number: 20030170691Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: December 19, 2002Publication date: September 11, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard